{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:52:11Z","timestamp":1791186731151,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006404.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000}}],"reference-count":97,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006404.pub5","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:48:01Z","timestamp":1760449681000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pyronaridine-artesunate for treating uncomplicated\n                    <i>Plasmodium falciparum<\/i>\n                    malaria"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3627-1016","authenticated-orcid":false,"given":"Tilly","family":"Fox","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenifer A","family":"Otieno","sequence":"additional","affiliation":[{"name":"Evidence for Health Research Unit; Kenya Medical Research Institute; Kisumu Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pryce","sequence":"additional","affiliation":[{"name":"Faculty of Life Sciences & Medicine; King's College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hine","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences; Liverpool School of Tropical Medicine; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"10.1002\/14651858.CD006404.pub5-BIB0001|cit1","unstructured":"World Health Organization World Malaria Report 2023 https:\/\/www.who.int\/publications\/i\/item\/9789240086173"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0002|cit2","unstructured":"World Health Organization World Malaria Report 2019 https:\/\/www.who.int\/publications\/i\/item\/9789241565721"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0003|cit3","unstructured":"World Health Organization WHO Guidelines for malaria. November 2024 https:\/\/www.who.int\/publications\/i\/item\/guidelines-for-malaria"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0004|cit4","unstructured":"World Health Organization WHO guidelines for the treatment of malaria. 2006 https:\/\/archives.who.int\/publications\/2006\/9241546948_eng.pdf"},{"issue":"5","key":"10.1002\/14651858.CD006404.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMoa0808859","article-title":"Artemisinin resistance in Plasmodium falciparum malaria","volume":"351","author":"Dondorp","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD006404.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1056\/NEJMc0805011","article-title":"Evidence of artemisinin-resistant malaria in western Cambodia","volume":"359","author":"Noedl","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006404.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/cid\/ciw388","article-title":"Declining efficacy of artemisinin combination therapy against P. Falciparum malaria on the Thai\u2013Myanmar border (2003\u20132013): the role of parasite genetic factors","volume":"63","author":"Phyo","year":"2016","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"Uwimana","year":"2020","journal-title":"Nature Medicine"},{"issue":"452","key":"10.1002\/14651858.CD006404.pub5-BIB0009|cit9","first-page":"1","article-title":"Artemisinin resistance \u2014 modelling the potential human and economic costs","volume":"13","author":"Lubell","year":"2014","journal-title":"Malaria Journal"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0010|cit10","unstructured":"World Health Organization Global plan for artemisinin resistance containment (GPARC) https:\/\/iris.who.int\/bitstream\/handle\/10665\/44482\/9789241500838_eng.pdf"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0011|cit11","unstructured":"Pan American Health Organization Framework for Artemisinin resistance prevention, containment, and elimination in South America https:\/\/www.iris.paho.org\/handle\/10665.2\/31208"},{"issue":"3","key":"10.1002\/14651858.CD006404.pub5-BIB0012|cit12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007483.pub2","article-title":"Artemisinin-based combination therapy for treating uncomplicated malaria","author":"Sinclair","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD006404.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0169-4758(91)90267-R","article-title":"Pyronaridine: a new antimalarial drug","volume":"7","author":"Fu","year":"1991","journal-title":"Parasitology Today"},{"issue":"1","key":"10.1002\/14651858.CD006404.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0035-9203(92)90414-8","article-title":"Studies on a new antimalarial compound: pyronaridine","volume":"86","author":"Chang","year":"1992","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0015|cit15","unstructured":"WHO TDR\/Medicines for Malaria Venture\/Shin Poong Pharmaceuticals Inc. sign agreement for development of pyronaridine-artesunate for treatment of malaria https:\/\/www.mmv.org\/newsroom\/press-releases\/tdrmedicines-malaria-ventureshin-poong-pharmaceuticals-inc-sign-agreement"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"e23398","DOI":"10.1002\/bip.23398","article-title":"Pyronaridine: an update of its pharmacological activities and mechanisms of action","volume":"112","author":"Bailly","year":"2021","journal-title":"Biopolymers"},{"issue":"10","key":"10.1002\/14651858.CD006404.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/jac\/dkad260","article-title":"Pyronaridine: a review of its clinical pharmacology in the treatment of malaria","volume":"78","author":"Chu","year":"2023","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD006404.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/00034983.1992.11812693","article-title":"In vitro activity of pyronaridine against African strains of Plasmodium falciparum","volume":"86","author":"Basco","year":"1992","journal-title":"Annals of Tropical Medicine and Parasitology"},{"issue":"1","key":"10.1002\/14651858.CD006404.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4269\/ajtmh.1988.38.24","article-title":"In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum","volume":"38","author":"Childs","year":"1988","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"3","key":"10.1002\/14651858.CD006404.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/jac\/42.3.333","article-title":"In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents","volume":"42","author":"Pradines","year":"1998","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD006404.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1128\/AAC.43.6.1525","article-title":"In vitro activities of pyronaridine, alone and in combination with other antimalarial drugs, against Plasmodium falciparum","volume":"43","author":"Ringwald","year":"1999","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD006404.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1383-5769(99)00028-8","article-title":"Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro","volume":"48","author":"Chavalitshewinkoon-Petmitr","year":"2000","journal-title":"Parasitology International"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1475-2875-8-79","article-title":"In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays","volume":"8","author":"Kurth","year":"2009","journal-title":"Malaria Journal"},{"issue":"12","key":"10.1002\/14651858.CD006404.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1128\/AAC.00801-10","article-title":"In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax","volume":"54","author":"Price","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD006404.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/00034983.1997.11813123","article-title":"The chemotherapy of rodent malaria. LV. Interactions between pyronaridine and artemisinin","volume":"91","author":"Peters","year":"1997","journal-title":"Annals of Tropical Medicine and Parasitology"},{"issue":"3","key":"10.1002\/14651858.CD006404.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.actatropica.2007.12.005","article-title":"Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo","volume":"105","author":"Vivas","year":"2008","journal-title":"Acta Tropica"},{"issue":"1","key":"10.1002\/14651858.CD006404.pub5-BIB0027|cit27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006404","article-title":"Pyronaridine for treating uncomplicated malaria","author":"Unnikrishnan","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006404.pub5-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006404.pub2","article-title":"Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria","author":"Bukirwa","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006404.pub5-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006404.pub3","article-title":"Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria","author":"Pryce","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006404.pub5-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006404.pub4","article-title":"Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria","author":"Pryce","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0031|cit31","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0032|cit32","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0033|cit33","unstructured":"World Health Organization Methods for surveillance of antimalarial drug efficacy. November 2009 https:\/\/www.who.int\/publications\/i\/item\/9789241597531"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0034|cit34","unstructured":"Retraction Watch Database https:\/\/www.retractiondatabase.org\/RetractionSearch"},{"issue":"7","key":"10.1002\/14651858.CD006404.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0036|cit36","unstructured":"World Health Organization Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. December 2003 https:\/\/www.who.int\/malaria\/publications\/atoz\/whohtmrbm200350\/en\/"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0037|cit37","unstructured":"Medical Dictionary for Regulatory Activities International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 2016"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0038|cit38","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.1.0"},{"issue":"32","key":"10.1002\/14651858.CD006404.pub5-BIB0039|cit39","first-page":"1","article-title":"Systematic reviews of adverse effects: framework for a structured approach","volume":"7","author":"Loke","year":"2007","journal-title":"BMC Medical Research Methodology"},{"issue":"157","key":"10.1002\/14651858.CD006404.pub5-BIB0040|cit40","first-page":"1","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"},{"issue":"10128","key":"10.1002\/14651858.CD006404.pub5-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","article-title":"Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial","volume":"391","author":"Sagara","year":"2018","journal-title":"Lancet"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD006404.pub5-BIB0042|cit42","first-page":"94","article-title":"Randomized trial to assess the effect on qtc interval of repeated treatment of uncomplicated malaria with acts in Bobo-Dioulasso, Burkina Faso: relation between parasitemia and prolonged QTc","volume":"97","author":"Kabore","year":"2017","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD006404.pub5-BIB0043|cit43","first-page":"317","article-title":"Assessment of the dynamics of Plasmodium falciparum parasitemia regarding three artemisinin combination regimens for acute uncomplicated malaria treatment, Banfora, Burkina Faso","volume":"97","author":"Soulama","year":"2017","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"2","key":"10.1002\/14651858.CD006404.pub5-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1473-3099(15)00318-7","article-title":"Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial","volume":"16","author":"Sagara","year":"2016","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0045|cit45","unstructured":"Beshir KB Diallo N Fofana B Traore A Kodio A Togo A Measuring the efficacy of four ACT regimens in Mali using qPCR-based estimates of Plasmodium falciparum clearance time 63rd Annual Meeting of the American Society of Tropical Medicine and Hygiene; 2013 Nov 2-6; New Orleans (LA)"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD006404.pub5-BIB0046|cit46","first-page":"479","article-title":"Safety and efficacy of repeated administration of pyronaridine-artesunate or dihydroartemisinin-piperaquine vs artesunate-amodiaquine in children and adult patients with acute uncomplicated Plasmodium sp malaria over of two years period at Banfora\/Niangoloko site in Burkina Faso","volume":"95","author":"Soulama","year":"2017","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1136\/bmjgh-2019-EDC.17","article-title":"SBOC 8459\u2005Assessment of parasite clearance after repeated treatment with artesunate amodiaquine, dihydroartemisinin-piperaquine, pyronaridine-artesunate in malaria patients in Burkina Faso","volume":"4","author":"Soulama","year":"2019","journal-title":"BMJ Global Health"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0048|cit48","first-page":"1","article-title":"A phase IIIb\/IV comparative, randomised, multi-centre, open label, parallel 3-arm clinical study to assess the safety and efficacy of repeated administration of four artemisinin-based combination therapy (ACT) over a two-year period in children and adult patients with acute uncomplicated Plasmodium sp. malaria","volume":"9","author":"Tekete","year":"2012","journal-title":"Jahrestreffen der AG Malaria der Sektion Antiparasitare Chemotherapie der Paul-Ehrlich-Gesellschaft fur Chemotherapie"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12936-025-05260-6","article-title":"Intermittent screening using ultra-sensitive malaria rapid diagnostic test and treatment with pyronaridine-artesunate compared to standard preventive treatment with sulfadoxine-pyrimethamine for malaria prevention in pregnant women in Kinshasa, DRC","volume":"24","author":"Tshiongo","year":"2025","journal-title":"Malaria Journal"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1186\/s13063-022-06884-8","article-title":"Comparison of intermittent screening (using ultra-sensitive malaria rapid diagnostic test) and treatment (using a newly registered antimalarial pyronaridine-artesunate \u2014 PYRAMAX\u00ae) to standard intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria in pregnant women living in endemic areas: ULTRAPYRAPREG","volume":"23","author":"Maketa","year":"2022","journal-title":"Trials"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0051|cit51","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12916-017-0948-8","article-title":"State of inequality in malaria intervention coverage in sub-Saharan African countries","volume":"15","author":"Galactionova","year":"2017","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0053|cit53","unstructured":"Malaria https:\/\/www.theglobalfund.org\/en\/malaria\/"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0054|cit54","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from https:\/\/gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0055|cit55","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2024"},{"issue":"10","key":"10.1002\/14651858.CD006404.pub5-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006491.pub4","article-title":"Mefloquine for preventing malaria during travel to endemic areas","author":"Tickell-Painter","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3390\/tropicalmed8040195","article-title":"Feasibility and acceptability of a strategy deploying multiple first-line artemisinin-based combination therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso","volume":"8","author":"Kabor\u00e9","year":"2023","journal-title":"Tropical Medicine and Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD006404.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/cid\/ciab425","article-title":"Efficacy, safety and tolerability of pyronaridine-artesunate in asymptomatic malaria-infected individuals: a randomized controlled trial","volume":"74","author":"Dabira","year":"2022","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12936-023-04574-7","article-title":"Efficacy and safety of pyronaridine\u2013artesunate versus artemether\u2013lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial","volume":"22","author":"Falade","year":"2023","journal-title":"Malaria Journal"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/S2666-5247(21)00192-0","article-title":"Pyronaridine\u2013artesunate or dihydroartemisinin\u2013piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ou\u00e9less\u00e9bougou, Mali: a four-arm, single-blind, phase 2\/3, randomised trial","volume":"3","author":"Stone","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/1475-2875-11-364","article-title":"Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial","volume":"11","author":"Kayentao","year":"2012","journal-title":"Malaria Journal"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0062|cit62","unstructured":"Pyronaridine artesunate 3:1 granule formulation vs. Coartem\u00a9 crushed tablets in P. falciparum malaria pediatric patients https:\/\/www.clinicaltrials.gov\/show\/NCT00541385"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD006404.pub5-BIB0063|cit63","first-page":"114","article-title":"Pyronaridine-artesunate versus artemether\/lumefantrine: efficacy in malaria patients with uncomplicated acute falciparum malaria: results of a pivotal phase III trial","volume":"79","author":"Kayentao","year":"2008","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"1","key":"10.1002\/14651858.CD006404.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12936-018-2340-3","article-title":"Pyronaridine\u2013artesunate and artemether\u2013lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non\u2011inferiority trial","volume":"17","author":"Roth","year":"2018","journal-title":"Malaria Journal"},{"issue":"14","key":"10.1002\/14651858.CD006404.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa1007125","article-title":"Pyronaridine-artesunate versus mefloquine plus artesunate for malaria","volume":"366","author":"Rueangweerayut","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006404.pub5-BIB0066|cit66","first-page":"30","article-title":"Efficacy and safety of pyronaridine\/artesunate fixed-dose combination compared with mefloquine plus artesunate in patients with acute uncomplicated Plasmodium falciparum malaria: results of a pivotal phase III trial","volume":"14","author":"Rueangweerayut","year":"2009","journal-title":"Tropical Medicine and International Health"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0067|cit67","unstructured":"Rueangweerayut R Phyo AP Uchaisin C Poravuth Y Quang Binh T Tinto H A randomized clinical trial comparing the efficacy and safety of fixed-dose pyronaridine-artesunate versus mefloquine plus artesunate in uncomplicated Plasmodium falciparum malaria Submitted under review; personal communication by email from Isabelle Borghini Fuhrer, Medicines for Malaria Venture"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0068|cit68","unstructured":"Pyronaridine artesunate (3:1) versus mefloquine artesunate in P. falciparum malaria patients https:\/\/www.clinicaltrials.gov\/show\/NCT00403260"},{"issue":"14","key":"10.1002\/14651858.CD006404.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa1007125","article-title":"Supplement to: Pyronaridine\u2013artesunate versus mefloquine plus artesunate for malaria","volume":"366","author":"Rueangweerayut","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"9724","key":"10.1002\/14651858.CD006404.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(10)60322-4","article-title":"Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial","volume":"375","author":"Tshefu","year":"2010","journal-title":"Lancet"},{"issue":"Suppl","key":"10.1002\/14651858.CD006404.pub5-BIB0071|cit71","first-page":"51","article-title":"Efficacy of pyronaridine\/artesunate in clinical trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an integrated analysis","volume":"81","author":"Duparc","year":"2009","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"Suppl","key":"10.1002\/14651858.CD006404.pub5-BIB0072|cit72","first-page":"101","article-title":"Safety of pyronaridine\/artesunate in clinical trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an integrated analysis","volume":"81","author":"Duparc","year":"2009","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12916-015-0535-9","article-title":"Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia","volume":"13","author":"Nelwan","year":"2015","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006404.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"e14501","DOI":"10.1371\/journal.pone.0014501","article-title":"Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial","volume":"6","author":"Poravuth","year":"2011","journal-title":"PLOS One"},{"issue":"Suppl","key":"10.1002\/14651858.CD006404.pub5-BIB0075|cit75","first-page":"101","article-title":"Safety of pyronaridine\/artesunate in clinical trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an integrated analysis","volume":"81","author":"Duparc","year":"2009","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"Suppl","key":"10.1002\/14651858.CD006404.pub5-BIB0076|cit76","first-page":"51","article-title":"Efficacy of pyronaridine\/artesunate in clinical trials in patients with uncomplicated acute Plasmodium falciparum or Plasmodium vivax malaria: results of an integrated analysis","volume":"81","author":"Duparc","year":"2009","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"8993","key":"10.1002\/14651858.CD006404.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(96)91558-5","article-title":"Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa","volume":"347","author":"Ringwald","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD006404.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"446","DOI":"10.4269\/ajtmh.1999.61.446","article-title":"Short report: effects of pyronaridine on gametocytes in patients with acute uncomplicated falciparum malaria","volume":"61","author":"Ringwald","year":"1999","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"4","key":"10.1002\/14651858.CD006404.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1086\/513942","article-title":"Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children","volume":"26","author":"Ringwald","year":"1998","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006404.pub5-BIB0080|cit80","first-page":"97","article-title":"Treatment of Korean vivax malaria patients with the fixed-dose combination of pyronaridine:artesunate","volume":"16","author":"Shin","year":"2011","journal-title":"Tropical Medicine and International Health"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0081|cit81","unstructured":"WANECAM trial authors Site data: Bobo, Burkina Faso (as supplied 6 July 2017) Data on file"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12936-021-03593-6","article-title":"Hepatic safety of repeated treatment with pyronaridine-artesunate versus artemether\u2013lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso","volume":"20","author":"Compaor\u00e9","year":"2021","journal-title":"Malaria Journal"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0083|cit83","unstructured":"WANECAM trial authors Site data: Bougala, Mali (as supplied 6 July 2017) Data on file"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0084|cit84","unstructured":"WANECAM trial authors Site data: Djoliba, Mali (as supplied 6 July 2017) Data on file"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0085|cit85","unstructured":"WANECAM trial authors Site data: Kolle, Mali (as supplied 6 July 2017) Data on file"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0086|cit86","unstructured":"WANECAM trial authors Site data: Mafrinyah, Guinea (as supplied 6 July 2017) Data on file"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0087|cit87","unstructured":"WANECAM trial authors Site data: Ouaga, Burkina Faso (as supplied 6 July 2017) Data on file"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0088|cit88","unstructured":"WANECAM trial authors Site data: Sotuba, Mali (as supplied 6 July 2017) Data on file"},{"issue":"6","key":"10.1002\/14651858.CD006404.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006404.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4269\/ajtmh.20-0185","article-title":"Efficacy and safety of Pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Myanmar","volume":"103","author":"Han","year":"2020","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"issue":"6","key":"10.1002\/14651858.CD006404.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"e1003669","DOI":"10.1371\/journal.pmed.1003669","article-title":"Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: a single-arm, open-label, cohort event monitoring study","volume":"16","author":"Lutete","year":"2021","journal-title":"PLOS Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006404.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"e00987","DOI":"10.1002\/prp2.987","article-title":"Prospective observational study to evaluate the clinical and biological safety profile of pyronaridine-artesunate in a rural health district in Burkina Faso","volume":"10","author":"Rouamba","year":"2022","journal-title":"Pharmacology research and perspectives"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1475-2875-12-70","article-title":"Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials","volume":"12","author":"Duparc","year":"2013","journal-title":"Malaria Journal"},{"issue":"6","key":"10.1002\/14651858.CD006404.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1086\/591096","article-title":"Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon","volume":"198","author":"Ramharter","year":"2008","journal-title":"Journal of Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006404.pub5-BIB0095|cit95","first-page":"1004","article-title":"Results of a randomized, multicentre, phase II, dose-ranging, clinical study to assess the safety and efficacy of fixed dose, orally administered pyronaridine and artesunate in adult patients with acute uncomplicated Plasmodium falciparum malaria","volume":"77","author":"Looareesuwan","year":"2007","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0096|cit96","unstructured":"World Health Organization WHO guidelines for malaria Geneva: World Health Organization; 16 October 2023. WHO\/UCN\/GMP\/2023.01 Rev1"},{"key":"10.1002\/14651858.CD006404.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"e065295","DOI":"10.1136\/bmjopen-2022-065295","article-title":"Efficacy and safety of pyronaridine artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial","volume":"13","author":"Djimbe","year":"2023","journal-title":"BMJ Open"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:02:41Z","timestamp":1791183761000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006404.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":97,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006404.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}